Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Cipla Ltd. Regulatory Filings 2020

Jul 21, 2020

59275_rns_2020-07-21_b2f6c0d6-2443-4196-8ee7-a238d6db2aec.pdf

Regulatory Filings

Open in viewer

Opens in your device viewer

Date: July 21, 2020

(1) BSE Ltd (2) National Stock Exchange of India Ltd Listing Department Listing Department Phiroze Jeejeebhoy Towers, Exchange Plaza, 5[th] floor, Dalal Street, Plot no. C/1, G Block, Mumbai - 400 001 Bandra Kurla Complex, Bandra (East), Mumbai - 400 051

Scrip Code: 500087

Scrip Code: CIPLA EQ

  • (3) SOCIETE DE LA BOURSE DE LUXEMBOURG Societe Anonyme 35A Boulevard Joseph II, L-1840 Luxembourg

Sub- Disclosure under Regulation 30 of SEBI (listing Obligation and Disclosure Requirements), 2015

Dear Sir/Madam,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015,and as per the Certificate of Amalgamation issued by the Registrar of Companies, Sri Lanka dated July 21, 2020, we hereby notify that the Company's step-down wholly owned subsidiary, Cipla Pharma Lanka (Private) Limited, Sri Lanka(CPL) has amalgamated with Company’s another step-down wholly owned subsidiary, Breathe Free Lanka (Private) Limited, Sri Lanka (BFL) , with effect from May 01, 2020.

Upon amalgamation into BFL, CPL stands dissolved without winding up.

A detailed disclosure as required under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 are enclosed as Annexure- I.

Thank you,

For Cipla Limited

RAJENDR Digitally signed by RAJENDRA CHOPRA DN: c=IN, o=Personal, 2.5.4.20=4987ad48c3965cfde78c8ea69e6f40ac91535876f12ba1fa5ba45cc5cc8db6cb, postalCode=122001, st=HARYANA, serialNumber=0be85c0408d0e3afd663669f531424 A CHOPRA 8a72fdcdf34d01d48d472d7cf9262696f6, cn=RAJENDRA CHOPRA cn=RAJENDRA CHOPRA

8a72fdcdf34d01d48d472d7cf9262696f6, cn=RAJENDRA CHOPRA cn=RAJENDRA CHOPRA Date: 2020.07.21 23:06:15 +05'30'


Rajendra Chopra Company Secretary

Enclosed:

  1. Details as per the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as Annexure - I

Annexure - I

Sr.No. Particulars Details
a) Details and reasons for restructuring Companies involved in restructuring:Cipla Pharma Lanka (Private) Limited, Sri Lanka (CPL)Breathe Free Lanka (Private) Limited, Sri Lanka (BFL)Type of restructuring- Amalgamation of step-down subsidiaries.**Reasons:**CPL was created as a (60:40) JV between Cipla (EU)Ltd ("Cipla EU"), wholly owned subsidiary of Cipla Limited, andthe local distributer (JV partner). Basis the “Share PurchaseAgreement” dated November 27, 2019, Cipla EU acquired JVpartner’s stake (400,000 LKR was paid for acquiring remaining40% stake) in CPL, making CPL a wholly owned subsidiary. As aresult, Cipla EU had two subsidiaries in Sri Lanka carrying onsimilar business.The amalgamation of CPL into BFL will consolidate the twoentities into one and help in focused operational efforts,rationalization, standardization and simplification of businessprocesses besides elimination of duplication which will result inoperational synergies and reduction of costs.
b) quantitative and/ or qualitative effectof restructuring All assets, liabilities, business operations and employees havebeen transferred to BFL
c) details of benefit, if any, to thepromoter/promotergroup/groupcompaniesfromsuchproposedrestructuring; Nil
d) brief details of change in shareholdingpattern (if any) of all entities. CPL will cease to exist and BFL will continue to remain whollyowned subsidiary.Effectively no change in shareholding pattern.